ETV6-NTRK3 gene fusion is the translocation of genetic material between chromosomes 12 and 15 (t(12;15)). This creates a new gene in which the 5' region of ETV6 is fused to the 3' region of NTRK3. The resulting transcript encodes and chimeric oncoprotein consisting of the helix-loop-helix (HLH) protein dimerization domain of ETV6 fused to the protein tyrosine kinase (PTK) domain of NTRK3.
The ETV6-NTRK3 gene fusion was originally identified in congenital fibrosarcoma but has since been identified in secretory breast carcinoma and its correlate in the salivary gland, mammary analogue secretory carcinoma.
NTRK3 inhibitors in clinical development
Entrectinib is a pan-NTRK, ALK, and ROS1 tyrosine kinase inhibitor in phase 2 clinical development.
References
ETV6-NTRK3 gene fusion Wikipedia(Text) CC BY-SA